Compare Cadila Healthcare with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ZYDUS LIFESCIENCES vs AUROBINDO PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ZYDUS LIFESCIENCES AUROBINDO PHARMA ZYDUS LIFESCIENCES/
AUROBINDO PHARMA
 
P/E (TTM) x 17.5 11.5 152.0% View Chart
P/BV x 2.8 1.4 198.2% View Chart
Dividend Yield % 1.0 0.8 130.2%  

Financials

 ZYDUS LIFESCIENCES   AUROBINDO PHARMA
EQUITY SHARE DATA
    ZYDUS LIFESCIENCES
Mar-21
AUROBINDO PHARMA
Mar-21
ZYDUS LIFESCIENCES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs5091,023 49.8%   
Low Rs259333 77.6%   
Sales per share (Unadj.) Rs147.5422.8 34.9%  
Earnings per share (Unadj.) Rs20.992.0 22.7%  
Cash flow per share (Unadj.) Rs28.0110.0 25.4%  
Dividends per share (Unadj.) Rs3.504.00 87.5%  
Avg Dividend yield %0.90.6 154.6%  
Book value per share (Unadj.) Rs126.9374.3 33.9%  
Shares outstanding (eoy) m1,023.74585.94 174.7%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.61.6 162.3%   
Avg P/E ratio x18.47.4 249.4%  
P/CF ratio (eoy) x13.76.2 222.7%  
Price / Book Value ratio x3.01.8 167.0%  
Dividend payout %16.84.3 385.4%   
Avg Mkt Cap Rs m393,092397,398 98.9%   
No. of employees `000NANA-   
Total wages/salary Rs m22,54835,350 63.8%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m151,022247,746 61.0%  
Other income Rs m4493,809 11.8%   
Total revenues Rs m151,471251,555 60.2%   
Gross profit Rs m31,33581,480 38.5%  
Depreciation Rs m7,24810,554 68.7%   
Interest Rs m1,688745 226.6%   
Profit before tax Rs m22,84873,990 30.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,47220,098 7.3%   
Profit after tax Rs m21,37653,892 39.7%  
Gross profit margin %20.732.9 63.1%  
Effective tax rate %6.427.2 23.7%   
Net profit margin %14.221.8 65.1%  
BALANCE SHEET DATA
Current assets Rs m87,160198,235 44.0%   
Current liabilities Rs m78,613106,652 73.7%   
Net working cap to sales %5.737.0 15.3%  
Current ratio x1.11.9 59.6%  
Inventory Days Days3319 173.5%  
Debtors Days Days7652 146.4%  
Net fixed assets Rs m140,943135,778 103.8%   
Share capital Rs m1,024586 174.8%   
"Free" reserves Rs m128,899218,713 58.9%   
Net worth Rs m129,923219,299 59.2%   
Long term debt Rs m6,0951,684 361.9%   
Total assets Rs m228,103334,013 68.3%  
Interest coverage x14.5100.3 14.5%   
Debt to equity ratio x00 610.9%  
Sales to assets ratio x0.70.7 89.3%   
Return on assets %10.116.4 61.8%  
Return on equity %16.524.6 67.0%  
Return on capital %18.033.8 53.3%  
Exports to sales %053.8 0.0%   
Imports to sales %10.516.4 64.3%   
Exports (fob) Rs mNA133,248 0.0%   
Imports (cif) Rs m15,91140,615 39.2%   
Fx inflow Rs m63,535133,248 47.7%   
Fx outflow Rs m15,91144,946 35.4%   
Net fx Rs m47,62488,302 53.9%   
CASH FLOW
From Operations Rs m32,93033,289 98.9%  
From Investments Rs m-7,2255,987 -120.7%  
From Financial Activity Rs m-25,489-13,648 186.8%  
Net Cashflow Rs m-90525,831 -3.5%  

Share Holding

Indian Promoters % 74.9 48.8 153.6%  
Foreign collaborators % 0.0 3.1 -  
Indian inst/Mut Fund % 15.4 38.3 40.3%  
FIIs % 2.5 20.8 12.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.1 48.2 52.1%  
Shareholders   408,017 338,639 120.5%  
Pledged promoter(s) holding % 0.0 14.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ZYDUS LIFESCIENCES With:   SUN PHARMA    CIPLA    LUPIN    DR. REDDYS LAB    PIRAMAL ENTERPRISES    

Yellow Ad

Advertisement

A One Stock Gift in 1990 Turns into Rs 130 Crores

In 2017, Ravi made headlines by calling a leading business news channel with a surprising announcement - his grandfather had left him 20,000 shares of only one stock.

And on the day of his call - these shares were worth Rs 130 crore.

Can you guess which is this company?

It's MRF.

Ravi's story is one of the amazing stories of becoming Crorepati from a single stock.

But the question is, how to find that one stock with crorepati potential?

To find the answer to this million-dollar question, join our 'One Stock Crorepati' MEGA summit on 30th June, where we will reveal details of what we call a potential 'crorepati' stock...

Learn more



Today's Market

Sensex Zooms 462 Points, Nifty Ends Near 15,700; Auto & FMCG Stocks Rally(Closing)

Indian share markets ended the week on a firm note tracking positive global cues.

Related Views on News

Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary (Views On News)

Jul 2, 2021

Here's why the company sold its business unit to Eugia Pharma Specialities.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks(Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Why Tata Power Share Price is Falling(Views On News)

Jun 14, 2022

Here's why shares of Tata Power have fallen in recent days.

Is it Time to Start Buying Stocks Selectively?(Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

When Will the Stock Market Recover?(Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ZYDUS LIFESCIENCES SHARE PRICE


Jun 24, 2022 (Close)

TRACK ZYDUS LIFESCIENCES

  • Track your investment in ZYDUS LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ZYDUS LIFESCIENCES

ZYDUS LIFESCIENCES - PARENT.DRUGS COMPARISON

COMPARE ZYDUS LIFESCIENCES WITH

MARKET STATS